-
Mashup Score: 0Leqembi recommended for treatment of early Alzheimer’s disease | European Medicines Agency (EMA) - 22 day(s) ago
Re-examination concludes that benefits outweigh risks in a restricted patient population
Source: www.ema.europa.euCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 0Leqembi recommended for treatment of early Alzheimer’s disease | European Medicines Agency (EMA) - 25 day(s) ago
Re-examination concludes that benefits outweigh risks in a restricted patient population
Source: www.ema.europa.euCategories: General Medicine News, Expert PicksTweet-
Leqembi recommended for treatment of early Alzheimer’s disease | European Medicines Agency (EMA) https://t.co/ZfFJcHIa5u
-
-
Mashup Score: 3Qdenga | European Medicines Agency (EMA) - 26 day(s) ago
dengue tetravalent vaccine (live, attenuated) Qdenga is a vaccine that helps protect against dengue disease. The vaccine can be given to adults, adolescents and children from 4 years of age. Dengue disease is a mosquito-borne tropical disease caused by the dengue virus, leading to mild, flu-like symptoms in most people. However, a small number of patients develop severe disease, with potentially fatal bleeding and organ damage. This vaccine contains attenuated (weakened) versions of dengue virus serotypes
Source: www.ema.europa.euCategories: General Medicine News, Infectious DiseaseTweet-
Qdenga, a vaccine against Dengue has been approved by the European Medicines Agency but not yet by @US_FDA anyone knows why or when? https://t.co/z4jPLe91CX
-
-
Mashup Score: 7
Home Events EMA and European Organisation for Research and Treatment of Cancer (EORTC) workshop: How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions? European Medicines Agency, Amsterdam, the Netherlands The European Medicines Agency (EMA) and the European Organisation for Research and Treatment of Cancer (EORTC) are jointly organising a workshop on how patient-reported outcomes (PRO) as well as health-related quality of life (HRQoL) data
Source: www.ema.europa.euCategories: General Medicine News, Oncologists1Tweet-
In February 2024, @EMA_News & EORTC held the joint workshop: How can patient-reported outcomes (PRO) and health-related #QualityofLife (HRQoL) data inform regulatory decisions? 🔍The report for the workshop is now available: https://t.co/oWNTU9sgqK #CancerResearch @EORTC_QLG https://t.co/Qfhjjl1lXs
-
-
Mashup Score: 6Arava | European Medicines Agency (EMA) - 3 month(s) ago
This is a summary of the European public assessment report (EPAR) for Arava. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Arava. Arava is a medicine that contains the active substance leflunomide. It is available as tablets (white and round: 10 and 100 mg; yellow and triangular: 20 mg). Arava is used to treat adults with active
Source: www.ema.europa.euCategories: General Medicine News, General HCPsTweet-
EMA Updated overview of leflunomide (Arava) https://t.co/LbuqzDdTvf https://t.co/npfsRDdFiP
-
-
Mashup Score: 41Arava | European Medicines Agency (EMA) - 3 month(s) ago
This is a summary of the European public assessment report (EPAR) for Arava. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Arava. Arava is a medicine that contains the active substance leflunomide. It is available as tablets (white and round: 10 and 100 mg; yellow and triangular: 20 mg). Arava is used to treat adults with active
Source: www.ema.europa.euCategories: General Medicine News, RheumatologyTweet-
EMA Updated overview of leflunomide (Arava) https://t.co/rr0YIuf6uR https://t.co/oR02J2VouO
-
-
Mashup Score: 10Eurneffy | European Medicines Agency - 3 month(s) ago
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Eurneffy, intended for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. The applicant for this medicinal product is ARS Pharmaceuticals IRL Limited. Eurneffy will be available as a 2 mg
Source: www.ema.europa.euCategories: General Medicine News, Allergy-ImmunologyTweet-
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product #Eurneffy (epinephrine, also known as adrenaline) intended for emergency treatment of allergic reactions (#anaphylaxis). https://t.co/oqpdylzdZg https://t.co/ETLEgjMKQX
-
-
Mashup Score: 9Eurneffy | European Medicines Agency - 5 month(s) ago
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Eurneffy, intended for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. The applicant for this medicinal product is ARS Pharmaceuticals IRL Limited. Eurneffy will be available as a 2 mg
Source: www.ema.europa.euCategories: General Medicine News, Allergy-ImmunologyTweet-
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product #Eurneffy (epinephrine, also known as adrenaline) intended for emergency treatment of allergic reactions (#anaphylaxis). https://t.co/oqpdylzdZg https://t.co/ETLEgjMKQX
-
-
Mashup Score: 1Have your say and help shape EMA’s future communications | European Medicines Agency - 6 month(s) ago
EMA has launched its biennial communication perception survey. The purpose of the survey is to collect feedback on EMA’s external communications from patients, consumers, healthcare professionals, animal health professionals, academics, media, other regulators and the pharmaceutical industry. EMA invites everyone to fill in the survey by Friday, 21 June 2024. The survey is anonymous and should take around 15 minutes to complete. The feedback will help EMA develop its future communication and engagement
Source: www.ema.europa.euCategories: General Medicine News, NeurologyTweet-
📌EAN Community News: Have your say in shaping @EMA_News future communications! 📎Fill out the survey: https://t.co/SpR90XNhqF https://t.co/Dnroya3en3
-
-
Mashup Score: 5
European Medicines Agency, Amsterdam, the Netherlands The European Medicines Agency (EMA) and the European Organisation for Research and Treatment of Cancer (EORTC) are co-chairing the Cancer Medicines Forum (CMF) which objective is to integrate the work of the academic sector into the regulatory decision-making process by acting as an unique channel between the regulator and academic clinical research. The deliverables of the CMF are aimed at supporting policy decisions to facilitate treatment optimisatio
Source: www.ema.europa.euCategories: General Medicine News, Onc News and JournalsTweet-
We are excited to be at the @EMA_News in Amsterdam for the #CancerMedicinesForum hybrid workshop! 🎥https://t.co/c8GztC9WP1 The CMF is reporting its observations and preliminary solutions to address #TreatmentOptimisation and discussing the proposed way forward. @EU2024BE https://t.co/qCaePFgdbw
-
Leqembi recommended for treatment of early Alzheimer’s disease | European Medicines Agency (EMA) https://t.co/ZfFJcHIa5u